Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 15 | 2023 | 123 | 3.610 |
Why?
|
| Skin | 11 | 2024 | 357 | 2.190 |
Why?
|
| Skin Diseases | 4 | 2024 | 76 | 1.930 |
Why?
|
| Dermatitis | 3 | 2024 | 27 | 1.820 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2023 | 651 | 1.560 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2022 | 13 | 1.480 |
Why?
|
| Chemokine CXCL10 | 10 | 2023 | 56 | 1.440 |
Why?
|
| Interleukin-16 | 5 | 2014 | 25 | 1.380 |
Why?
|
| Receptors, CXCR3 | 7 | 2023 | 35 | 1.230 |
Why?
|
| Autoimmune Diseases | 2 | 2021 | 220 | 1.190 |
Why?
|
| Scleroderma, Localized | 3 | 2023 | 10 | 1.180 |
Why?
|
| Chemokines | 2 | 2019 | 93 | 1.120 |
Why?
|
| Immunologic Memory | 4 | 2021 | 283 | 0.950 |
Why?
|
| Melanocytes | 4 | 2023 | 77 | 0.950 |
Why?
|
| S100 Proteins | 1 | 2024 | 19 | 0.920 |
Why?
|
| Signal Transduction | 7 | 2022 | 2903 | 0.900 |
Why?
|
| Homeostasis | 2 | 2024 | 346 | 0.850 |
Why?
|
| Janus Kinase Inhibitors | 4 | 2023 | 17 | 0.740 |
Why?
|
| Immunotherapy | 3 | 2023 | 228 | 0.740 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2020 | 3 | 0.720 |
Why?
|
| Pigmentation Disorders | 1 | 2020 | 8 | 0.720 |
Why?
|
| Immunologic Factors | 1 | 2021 | 103 | 0.680 |
Why?
|
| Epidermis | 2 | 2018 | 35 | 0.680 |
Why?
|
| Dog Diseases | 1 | 2020 | 53 | 0.680 |
Why?
|
| Animals | 23 | 2024 | 19650 | 0.670 |
Why?
|
| Th1 Cells | 3 | 2022 | 177 | 0.660 |
Why?
|
| Lipopolysaccharides | 2 | 2012 | 627 | 0.640 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 623 | 0.640 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 40 | 0.600 |
Why?
|
| Interleukin-15 | 1 | 2018 | 24 | 0.600 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2012 | 391 | 0.590 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 986 | 0.580 |
Why?
|
| Chemokine CXCL9 | 6 | 2023 | 24 | 0.580 |
Why?
|
| Mice | 17 | 2023 | 10294 | 0.570 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 244 | 0.570 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 207 | 0.550 |
Why?
|
| Fibrosis | 3 | 2023 | 153 | 0.530 |
Why?
|
| Antibodies | 1 | 2017 | 179 | 0.510 |
Why?
|
| Mannose | 2 | 2012 | 21 | 0.500 |
Why?
|
| Humans | 29 | 2024 | 59389 | 0.460 |
Why?
|
| Antigens, Bacterial | 2 | 2012 | 200 | 0.460 |
Why?
|
| Protein Precursors | 2 | 2011 | 75 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 474 | 0.440 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 2053 | 0.440 |
Why?
|
| Biomarkers | 4 | 2024 | 1307 | 0.430 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 3231 | 0.430 |
Why?
|
| Cell Migration Inhibition | 1 | 2012 | 7 | 0.410 |
Why?
|
| Ligands | 4 | 2023 | 411 | 0.410 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 62 | 0.400 |
Why?
|
| ADAM Proteins | 1 | 2012 | 34 | 0.390 |
Why?
|
| Skin Neoplasms | 3 | 2014 | 397 | 0.390 |
Why?
|
| Keratinocytes | 3 | 2023 | 63 | 0.390 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2011 | 49 | 0.380 |
Why?
|
| Sezary Syndrome | 2 | 2011 | 2 | 0.380 |
Why?
|
| Cytokines | 6 | 2024 | 915 | 0.380 |
Why?
|
| Bleomycin | 2 | 2023 | 32 | 0.380 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2010 | 6 | 0.360 |
Why?
|
| Inflammation | 3 | 2023 | 1099 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 588 | 0.330 |
Why?
|
| Flow Cytometry | 4 | 2018 | 645 | 0.320 |
Why?
|
| Interferon-gamma | 5 | 2018 | 551 | 0.320 |
Why?
|
| Immunity, Innate | 1 | 2013 | 774 | 0.280 |
Why?
|
| Simvastatin | 2 | 2017 | 26 | 0.250 |
Why?
|
| Immunity, Cellular | 2 | 2019 | 171 | 0.250 |
Why?
|
| Genetic Therapy | 1 | 2011 | 733 | 0.230 |
Why?
|
| Neoplasms | 1 | 2014 | 1231 | 0.220 |
Why?
|
| Dogs | 2 | 2023 | 314 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 65 | 0.210 |
Why?
|
| Proteomics | 1 | 2024 | 263 | 0.200 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 39 | 0.200 |
Why?
|
| Connective Tissue Diseases | 1 | 2022 | 10 | 0.190 |
Why?
|
| Th2 Cells | 1 | 2022 | 99 | 0.190 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 1206 | 0.190 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 207 | 0.190 |
Why?
|
| Up-Regulation | 1 | 2023 | 365 | 0.190 |
Why?
|
| Scleroderma, Systemic | 1 | 2021 | 20 | 0.190 |
Why?
|
| Fibroblasts | 1 | 2023 | 377 | 0.180 |
Why?
|
| Biological Products | 1 | 2022 | 90 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1479 | 0.180 |
Why?
|
| Cross-Priming | 1 | 2020 | 16 | 0.170 |
Why?
|
| Melanoma, Experimental | 1 | 2020 | 40 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 446 | 0.170 |
Why?
|
| Transcriptome | 1 | 2023 | 340 | 0.170 |
Why?
|
| Autoantigens | 1 | 2021 | 129 | 0.170 |
Why?
|
| Cells, Cultured | 3 | 2014 | 2092 | 0.170 |
Why?
|
| Cell Movement | 2 | 2019 | 428 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 214 | 0.160 |
Why?
|
| Phenotype | 2 | 2024 | 1137 | 0.160 |
Why?
|
| Interferon Type I | 1 | 2020 | 169 | 0.160 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 121 | 0.150 |
Why?
|
| Male | 11 | 2024 | 27747 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 204 | 0.140 |
Why?
|
| Gene Expression | 1 | 2020 | 809 | 0.140 |
Why?
|
| Female | 11 | 2024 | 30724 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 68 | 0.140 |
Why?
|
| Blister | 1 | 2017 | 17 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2018 | 343 | 0.140 |
Why?
|
| Skin Physiological Phenomena | 1 | 2014 | 16 | 0.120 |
Why?
|
| Skin Pigmentation | 1 | 2014 | 29 | 0.120 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 3 | 0.110 |
Why?
|
| Receptors, CCR4 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2020 | 808 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 46 | 0.110 |
Why?
|
| Middle Aged | 8 | 2024 | 16314 | 0.110 |
Why?
|
| Immunity | 1 | 2014 | 101 | 0.110 |
Why?
|
| Wound Healing | 1 | 2014 | 174 | 0.110 |
Why?
|
| Lymphocyte Activation | 2 | 2012 | 743 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 98 | 0.100 |
Why?
|
| ADAM17 Protein | 1 | 2012 | 9 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2012 | 62 | 0.100 |
Why?
|
| Prognosis | 2 | 2021 | 1597 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2011 | 8 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2013 | 185 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 234 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 191 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2012 | 215 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 331 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2012 | 359 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 108 | 0.090 |
Why?
|
| Lentivirus | 1 | 2011 | 63 | 0.090 |
Why?
|
| Mice, SCID | 1 | 2011 | 513 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 278 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2011 | 382 | 0.080 |
Why?
|
| Adult | 6 | 2024 | 15683 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 448 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1368 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1304 | 0.070 |
Why?
|
| Young Adult | 3 | 2023 | 4272 | 0.060 |
Why?
|
| Adolescent | 3 | 2023 | 5838 | 0.060 |
Why?
|
| Janus Kinase 1 | 1 | 2023 | 10 | 0.060 |
Why?
|
| Acrylamides | 1 | 2023 | 15 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2023 | 106 | 0.050 |
Why?
|
| Aged | 3 | 2020 | 13406 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2023 | 155 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2022 | 17 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2022 | 17 | 0.050 |
Why?
|
| Child | 2 | 2022 | 4189 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2023 | 223 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 287 | 0.050 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2020 | 5 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 35 | 0.040 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 45 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 56 | 0.040 |
Why?
|
| Vaccinia virus | 1 | 2020 | 70 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2014 | 941 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 54 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2023 | 5281 | 0.040 |
Why?
|
| Piperidines | 1 | 2020 | 55 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 131 | 0.040 |
Why?
|
| Stem Cell Factor | 1 | 2018 | 26 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 129 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 410 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 2338 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 858 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 2380 | 0.040 |
Why?
|
| Chemokine CXCL11 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Suction | 1 | 2017 | 33 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2017 | 11 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5119 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 267 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 355 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 2052 | 0.030 |
Why?
|
| Pigmentation | 1 | 2014 | 25 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 35 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 715 | 0.030 |
Why?
|
| Chemokine CCL22 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 13 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1051 | 0.030 |
Why?
|
| Chemokines, CXC | 1 | 2012 | 29 | 0.030 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2012 | 53 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 392 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 29 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 52 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2011 | 33 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 52 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 356 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 288 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 394 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 656 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2012 | 515 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1553 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1951 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1555 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1151 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1552 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 2456 | 0.010 |
Why?
|